{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:26:17Z","timestamp":1787678777565,"version":"build-2784847793"},"reference-count":51,"publisher":"BMJ","issue":"9","funder":[{"name":"Italian Society for Rheumatology"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,8,10]]},"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>These analyses aim to comparatively evaluate the persistence on treatment of different biological disease-modifying antirheumatic drugs (bDMARDs) when administered in monotherapy compared with combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) patients receiving first-line biologics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This is a retrospective observational study on Administrative Healthcare Databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were extracted from healthcare databases of the Lombardy Region, Italy (2004\u20132013), as a part of the RECord-linkage On Rheumatic Diseases study, on behalf of the Italian Society for Rheumatology. Analyses included patients with RA starting first-line approved course of bDMARDs and evaluated drug survival by using Cox proportional hazard models. Results are presented as HRs and 95%\u2009CI, crude and adjusted for prespecified confounders (age, sex, disease duration, Charlson Comorbidity Index (CCI), previous infections, use of concomitant glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>4478 patients with RA were included (17.84% monotherapy). Etanercept, adalimumab and infliximab were the most prescribed first-line biologics. bDMARD monotherapy was associated with longer disease duration, higher CCI, lower glucocorticoids and NSAIDs use. Compared with monotherapy, combination associated with a lower risk of failure (adjusted HR 0.79, 95%\u2009CI 0.72 to 0.88). Among monotherapies, considering etanercept as reference, adalimumab (1.28, 95% CI 1.03 to 1.59) and infliximab (2.41, 95% CI 1.85 to 3.15) had higher risk of failure. Concomitant methotrexate (0.78, 95% CI 0.70 to 0.87), leflunomide (0.80, 95% CI 0.65 to 0.98) or csDMARD combinations (0.77, 95% CI 0.68 to 0.87) reduced the risk of bDMARD withdrawal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adalimumab and infliximab monotherapies show lower retention rate compared with etanercept. The relatively small number of therapeutic courses different from tumour necrosis factor (TNF) inhibitors makes more difficult to achieve conclusive results with other biologics. Concomitant methotrexate, leflunomide and csDMARDs combination associate with longer survival on bDMARD. Our data confirm the effectiveness of the current practices in the choice of etanercept as first-line anti-TNF monotherapy and strengthen the currently recommended use of bDMARDs in combination with csDMARDs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-021447","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T09:28:36Z","timestamp":1536658116000},"page":"e021447","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases"],"prefix":"10.1136","volume":"8","author":[{"given":"Ettore","family":"Silvagni","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Rheumatology Unit, University of Ferrara, Cona (Ferrara), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology Unit, University of Ferrara, Cona (Ferrara), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Carrara","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zanetti","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology Unit, University of Ferrara, Cona (Ferrara), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Scir\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology Unit, University of Ferrara, Cona (Ferrara), Italy"},{"name":"Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"2025101814034607000_8.9.e021447.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025101814034607000_8.9.e021447.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev374"},{"key":"2025101814034607000_8.9.e021447.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202515"},{"key":"2025101814034607000_8.9.e021447.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769"},{"key":"2025101814034607000_8.9.e021447.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"2025101814034607000_8.9.e021447.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2025101814034607000_8.9.e021447.7","doi-asserted-by":"crossref","first-page":"kew271","DOI":"10.1093\/rheumatology\/kew271","article-title":"Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1","volume":"70","author":"Choy","year":"2016","journal-title":"Rheumatology"},{"key":"2025101814034607000_8.9.e021447.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210297"},{"key":"2025101814034607000_8.9.e021447.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204761"},{"key":"2025101814034607000_8.9.e021447.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21876"},{"key":"2025101814034607000_8.9.e021447.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100208"},{"key":"2025101814034607000_8.9.e021447.12","doi-asserted-by":"crossref","unstructured":"Mehta N , Schneider LK , McCardell E . Rheumatoid arthritis: selecting monotherapy versus combination therapy. J Clin Rheumatol 2017 (Published Online First: 18 Jan 2017).doi:10.1097\/RHU.0000000000000410","DOI":"10.1097\/RHU.0000000000000410"},{"key":"2025101814034607000_8.9.e021447.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203485"},{"key":"2025101814034607000_8.9.e021447.14","doi-asserted-by":"publisher","DOI":"10.1186\/ar1933"},{"key":"2025101814034607000_8.9.e021447.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080889"},{"key":"2025101814034607000_8.9.e021447.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139774"},{"key":"2025101814034607000_8.9.e021447.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006029","article-title":"A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic diseases study of the italian society for rheumatology","volume":"5","author":"Carrara","year":"2015","journal-title":"BMJ Open"},{"key":"2025101814034607000_8.9.e021447.18","unstructured":"Generali E , Carrara G , Selmi C , et al . Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clin Exp Rheumatol. . 2018;Mar-Apr;36(2):310-313."},{"key":"2025101814034607000_8.9.e021447.19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000523"},{"key":"2025101814034607000_8.9.e021447.20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acr.21959","article-title":"Systematic review of validation studies of the use of administrative data to identify serious infections","volume":"65","author":"Barber","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025101814034607000_8.9.e021447.21","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"2025101814034607000_8.9.e021447.22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40744-015-0008-9","article-title":"Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a us registry population","volume":"2","author":"Pappas","year":"2015","journal-title":"Rheumatol Ther"},{"key":"2025101814034607000_8.9.e021447.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev216"},{"key":"2025101814034607000_8.9.e021447.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2025101814034607000_8.9.e021447.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev019"},{"key":"2025101814034607000_8.9.e021447.26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/acr.22510","article-title":"Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients","volume":"67","author":"Zhang","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2025101814034607000_8.9.e021447.27","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025101814034607000_8.9.e021447.28","first-page":"429","article-title":"Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70","volume":"6","author":"Orme","year":"2012","journal-title":"Biologics"},{"key":"2025101814034607000_8.9.e021447.29","doi-asserted-by":"publisher","DOI":"10.1186\/ar2084"},{"key":"2025101814034607000_8.9.e021447.30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025101814034607000_8.9.e021447.31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"Frazier-Mironer","year":"2014","journal-title":"Joint Bone Spine"},{"key":"2025101814034607000_8.9.e021447.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111125"},{"key":"2025101814034607000_8.9.e021447.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169946","article-title":"EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry","volume":"12","author":"J\u00f8rgensen","year":"2017","journal-title":"PLoS One"},{"key":"2025101814034607000_8.9.e021447.34","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65510"},{"key":"2025101814034607000_8.9.e021447.35","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025101814034607000_8.9.e021447.36","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.5.409"},{"key":"2025101814034607000_8.9.e021447.37","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s12325-016-0372-z","article-title":"Efficacy and treatment costs of monotherapy with bdmards in the treatment of rheumatoid arthritis in patients intolerant to or inappropriate to continue treatment with methotrexate","volume":"33","author":"Batticciotto","year":"2016","journal-title":"Adv Ther"},{"key":"2025101814034607000_8.9.e021447.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205752"},{"key":"2025101814034607000_8.9.e021447.39","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s10067-017-3779-2","article-title":"Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and\/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study","volume":"36","author":"Mueller","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025101814034607000_8.9.e021447.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208426"},{"key":"2025101814034607000_8.9.e021447.41","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21847"},{"key":"2025101814034607000_8.9.e021447.42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10067-016-3435-2","article-title":"Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis","volume":"36","author":"Alfonso-Cristancho","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025101814034607000_8.9.e021447.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"2025101814034607000_8.9.e021447.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151014"},{"key":"2025101814034607000_8.9.e021447.45","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1349-y"},{"key":"2025101814034607000_8.9.e021447.46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh508"},{"key":"2025101814034607000_8.9.e021447.47","doi-asserted-by":"publisher","DOI":"10.1186\/ar4521"},{"key":"2025101814034607000_8.9.e021447.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200003"},{"key":"2025101814034607000_8.9.e021447.49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/acr.22840","article-title":"Medication persistence of disease-modifying antirheumatic drugs and anti-tumor necrosis factor agents in a cohort of patients with rheumatoid arthritis in Brazil","volume":"68","author":"Acurcio","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025101814034607000_8.9.e021447.50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/ar1151","article-title":"Measuring effectiveness of drugs in observational databanks: promises and perils","volume":"6","author":"Krishnan","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"2025101814034607000_8.9.e021447.51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4212\/cjhp.v68i3.1457","article-title":"An introduction to health care administrative data","volume":"68","author":"Cadarette","year":"2015","journal-title":"Can J Hosp Pharm"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-021447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:03:56Z","timestamp":1760821436000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-021447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,11]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1136\/bmjopen-2017-021447"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-021447","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}